InsidersTradesSigma
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (0 ops.)
Discover the complete record of transactions filed by M. Colpan, Director. Officer active across 1 companies, notably Qiagen N.V.. Aggregated, 120 disclosures have been recorded. The latest transaction was disclosed on 19 August 2024 — Sale. Regulator: AFM. All data is accessible without signup.
Declarations120 total
-9,156 shares
Restricted share award
AFM:189033·
4,618 shares
Restricted share award
AFM:189004·
Ideal exit: 24 Nov 2026 (T+270)
-4,490 shares
Restricted share award
AFM:188862·
-8,804 shares
Gewoon aandeel
AFM:185870·
-2,458 shares
Restricted share award
AFM:170825·
-4,910 shares
Gewoon aandeel
AFM:169256·
€1m-27,616 shares@ €42.19330.012% mcap0.6% of flow
Gewoon aandeel
AFM:162495·
€4m-98,544 shares@ €42.26310.043% mcap2.1% of flow
Gewoon aandeel
AFM:162431·
€2m-50,973 shares@ €42.07470.022% mcap1.1% of flow
Gewoon aandeel
AFM:162353·
€3m-61,367 shares@ €41.7940.026% mcap1.3% of flow
Gewoon aandeel
AFM:162320·
7,056 shares
Restricted share award
AFM:154858·
Ideal exit: 25 Nov 2024 (T+270)
-5,599 shares
Restricted share award
AFM:154972·
-2,992 shares
Restricted share award
AFM:154855·
-12,710 shares
Gewoon aandeel
AFM:153268·
-1,773 shares
Restricted share award
AFM:137660·
-457 shares
Restricted share award
AFM:132941·
-544 shares
Restricted share award
AFM:120923·
-3,192 shares
Restricted share award
AFM:120855·
-6,446 shares
Restricted share award
AFM:106800·
-4,414 shares
Restricted share award
AFM:106758·
7,482 shares
Restricted share award
AFM:106757·
Ideal exit: 23 Nov 2021 (T+270)
€12m-274,784 shares@ €45.44840.13% mcap6.3% of flow
Gewoon aandeel
AFM:106340·
€23m-495,586 shares@ €45.74820.23% mcap11.5% of flow
Gewoon aandeel
AFM:106282·
€45m-1,080,308 shares@ €41.89510.46% mcap23.0% of flow
Gewoon aandeel
AFM:103242·
€19m-462,264 shares@ €42.17850.20% mcap9.9% of flow
Gewoon aandeel
AFM:103198·
25 of 120 declarations
About M. Colpan
M. Colpan is a Director or Supervisory Board member at Qiagen N.V. He contributes to the governance of the company and strategic decision-making. With expertise in the biopharmaceutical sector, he plays a key role in guiding projects and growth initiatives.
